A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 17 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Jun 2024 According to a Dermavant Sciences media release, company announced that Japan Tobacco has received approval in Japan for tapinarof cream, 1% for the treatment of patients 12 years of age and older with atopic dermatitis.
21 May 2024 According to a Dermavant Sciences media release, data from the study were presented in the Journal of the American Academy of Dermatology.
21 May 2024 Results presented in the Dermavant Sciences Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com